Skip to main content

Items where Author, Editor or other role is "Garrett, Michelle"

Group by: Creator's name | Item Type | Date | No Grouping
Jump to: A | B | C | D | F | G | H | J | L | M | O | P | R | S | T | W | Y
Number of items: 44.

A

Ahmad, Bilal, Friar, Emily P., Vohra, Muhammad Sufyan, Garrett, Michelle D., Serpell, Christopher J., Fong, Isabel Lim, Wong, Eng Hwa (2020) Mechanisms of action for the anti-obesogenic activities of phytochemicals. Phytochemistry, 180 . Article Number 112513. ISSN 0031-9422. (doi:10.1016/j.phytochem.2020.112513) (KAR id:84469)
[thumbnail of Proof Read_Phytochemistry 25_09_2020(1).pdf]
Preview
[thumbnail of Proof Read_Phytochemistry 25_09_2020(1).docx]

Anderson, Victoria E., Walton, Michael I., Eve, Paul D., Boxall, Katherine J., Antoni, Laurent, Caldwell, John J., Aherne, Wynne, Pearl, Laurence H., Oliver, Antony W., Collins, Ian, and others. (2011) CCT241533 Is a Potent and Selective Inhibitor of CHK2 that Potentiates the Cytotoxicity of PARP Inhibitors. Cancer Research, 71 (2). pp. 463-472. ISSN 0008-5472. (doi:10.1158/0008-5472.CAN-10-1252) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58568)

B

Breeds, Nathan (2020) Investigating mechanisms of acquired resistance to AT13148, an AGC kinase inhibitor. Doctor of Philosophy (PhD) thesis, University of Kent,. (KAR id:82198)
[thumbnail of 279Investigating_mechansims_of_acquired_resistance_to_AT13148_an_AGC_kinase_inhi.pdf]
Preview

Banerji, Udai, Dean, Emma J., Pérez-Fidalgo, J. Alejandro, Batist, Gerald, Bedard, Philippe L., You, Benoit, Westin, Shannon N., Kabos, Peter, Garrett, Michelle D., Tall, Mathew, and others. (2018) A Phase 1 open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers. Clinical Cancer Research, 24 (9). pp. 2050-2059. ISSN 1078-0432. E-ISSN 1557-3265. (doi:10.1158/1078-0432.CCR-17-2260) (KAR id:63859)
[thumbnail of Banerji et al 2017 R2-Merged manuscript and Figures-Post decision-accepted.pdf]
Preview
[thumbnail of Supplementary data]

Borst, Gerben R., McLaughlin, Martin, Kyula, Joan N., Neijenhuis, Sari, Khan, Aadil, Good, James, Zaidi, Shane, Powell, Ned G., Meier, Pascal, Collins, Ian, and others. (2012) Targeted Radiosensitization by the Chk1 Inhibitor SAR-020106. International Journal of Radiation Oncology Biology Physics, 85 (4). pp. 1110-1118. ISSN 0360-3016. (doi:10.1016/j.ijrobp.2012.08.006) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58562)

Banerji, Udai, van Doorn, Leni, Papadatos-Pastos, Dionysis, Kristeleit, Rebecca, Debnam, Phillip, Tall, Matthew, Stewart, Adam, Raynaud, Florence, Garrett, Michelle Dawn, Toal, Martin, and others. (2012) A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors. Clinical Cancer Research, 18 (9). pp. 2687-2694. ISSN 1078-0432. (doi:10.1158/1078-0432.CCR-11-3165) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58565)

Bernhard, Eric J., Stockwell, Simon R., Platt, Georgina, Barrie, S. Elaine, Zoumpoulidou, Georgia, te Poele, Robert H., Aherne, G. Wynne, Wilson, Stuart C., Sheldrake, Peter, McDonald, Edward, and others. (2012) Mechanism-Based Screen for G1/S Checkpoint Activators Identifies a Selective Activator of EIF2AK3/PERK Signalling. PLoS ONE, 7 (1). e28568. ISSN 1932-6203. (doi:10.1371/journal.pone.0028568) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58566)

C

Carden, C. P., Stewart, A., Thavasu, P., Kipps, E., Pope, L., Crespo, M., Miranda, S., Attard, G., Garrett, Michelle D., Clarke, P. A., and others. (2012) The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer. Molecular Cancer Therapeutics, 11 (7). pp. 1609-1617. ISSN 1535-7163. (doi:10.1158/1535-7163.MCT-11-0996) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58563)

Caldwell, John J., Welsh, Emma J., Matijssen, Cornelis, Anderson, Victoria E., Antoni, Laurent, Boxall, Kathy, Urban, Frederique, Hayes, Angela, Raynaud, Florence I., Rigoreau, Laurent J. M., and others. (2010) Structure-Based Design of Potent and Selective 2-(Quinazolin-2-yl)phenol Inhibitors of Checkpoint Kinase 2. Journal of Medicinal Chemistry, 54 (2). pp. 580-590. ISSN 0022-2623. (doi:10.1021/jm101150b) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58571)

D

Dora, Nova Olympia, Blackburn, Edith, Boles, Jessica E., Williams, George T., White, Lisa J., Turner, Scarlett, Hothersall, Trevor, Askwith, Trevor, Doolan, Jack, Mulvihill, Daniel P., and others. (2021) Supramolecular self-associating amphiphiles (SSAs) as nanoscale enhancers of cisplatin anticancer activity. RSC Advances, 11 . pp. 14213-14217. ISSN 2046-2069. (doi:10.1039/D1RA02281D) (KAR id:87520)
[thumbnail of d1ra02281d.pdf]
Preview
[thumbnail of revised supplementary information.pdf]
Preview

Dora, Nova Olympia (2020) Development of novel antimicrobials as potential anticancer treatments. Master of Science by Research (MScRes) thesis, University of Kent,. (Access to this publication is currently restricted. You may be able to access a copy if URLs are provided) (KAR id:81198)
[thumbnail of 233Thesis.pdf]

Doyle, Kevin (2016) Investigating the effects of novel AKT inhibitors on the insulin/IGF-1 like signalling pathway in C. elegans. Master of Research (MRes) thesis, University of Kent,. (doi:10.22024/UniKent/01.02.59976) (Access to this publication is currently restricted. You may be able to access a copy if URLs are provided) (KAR id:59976)
[thumbnail of 70Kevin Doyle dissertation.pdf]

F

Fenton, Tim R., Garrett, Michelle D., Michaelis, Martin, Wass, Mark N. (2018) Meeting Abstracts of the BACR conference: response and resistance in cancer therapy. Cancer Drug Resistance, 1 . pp. 266-302. E-ISSN 2578-532X. (doi:10.20517/cdr.2018.18) (KAR id:73043)
[thumbnail of __bodiam_CUR_ecs33_My Files_Cancer.pdf]
Preview

Fenton, Tim R., Garrett, Michelle D., Wass, Mark N., Michaelis, Martin (2018) What really matters - response and resistance in cancer therapy. Cancer Drug Resistance, 2018 (1). pp. 200-203. ISSN 2578-532X. (doi:10.20517/cdr.2018.19) (KAR id:71006)
[thumbnail of 2882.pdf]
Preview

G

Grimsley, Helen Elizabeth (2021) Investigating mechanisms of acquired drug resistance in Triple Negative Breast Cancer. Doctor of Philosophy (PhD) thesis, University of Kent,. (doi:10.22024/UniKent/01.02.88062) (KAR id:88062)
[thumbnail of 180Thesis_November_2020_viva_revision.pdf]
Preview

Garrett, Michelle D. (2014) JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells. Oncogene, 33 . pp. 1148-1157. (doi:10.1038/onc.2013.46) (KAR id:86611)
[thumbnail of Walters et al 2014.pdf]
Preview

Grimshaw, K. M., Hunter, L.-J. K., Yap, T. A., Heaton, S. P., Walton, M. I., Woodhead, S. J., Fazal, L., Reule, M., Davies, T. G., Seavers, L. C., and others. (2010) AT7867 Is a Potent and Oral Inhibitor of AKT and p70 S6 Kinase That Induces Pharmacodynamic Changes and Inhibits Human Tumor Xenograft Growth. Molecular Cancer Therapeutics, 9 (5). pp. 1100-1110. ISSN 1535-7163. (doi:10.1158/1535-7163.MCT-09-0986) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58573)

H

Hilton, Kira L.F., Manwani, Chandni, Boles, Jessica E., White, Lisa J., Ozturk, Sena, Garrett, Michelle D., Hiscock, Jennifer R. (2021) The phospholipid membrane compositions of bacterial cells, cancer cell lines and biological samples from cancer patients. Chemical Science, 12 . pp. 13273-13282. ISSN 2041-6520. (doi:10.1039/D1SC03597E) (KAR id:90289)
[thumbnail of d1sc03597e.pdf]
Preview
[thumbnail of manuscript revised final.docx]

Hilton, Stephen, Naud, Sebastien, Caldwell, John J., Boxall, Kathy, Burns, Samantha, Anderson, Victoria E., Antoni, Laurent, Allen, Charlotte E., Pearl, Laurence H., Oliver, Antony W., and others. (2009) Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2. Bioorganic & Medicinal Chemistry, 18 (2). pp. 707-718. ISSN 0968-0896. (doi:10.1016/j.bmc.2009.11.058) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58576)

J

Jakubowski, Jasmine Marie (2019) Investigating mechanisms of acquired resistance to the AKT inhibitor capivasertib (AZD5363). Doctor of Philosophy (PhD) thesis, University of Kent,. (Access to this publication is currently restricted. You may be able to access a copy if URLs are provided) (KAR id:80960)
[thumbnail of 174Investigating_mechanisms_of_acquired_resistance_to_the_AKT_inhibitor_capivase.pdf]

L

Lainchbury, Michael, Matthews, Thomas P., McHardy, Tatiana, Boxall, Kathy J., Walton, Michael I., Eve, Paul D., Hayes, Angela, Valenti, Melanie R., de Haven Brandon, Alexis K., Box, Gary, and others. (2012) Discovery of 3-Alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as Selective, Orally Bioavailable CHK1 Inhibitors. Journal of Medicinal Chemistry, 55 (22). pp. 10229-10240. ISSN 0022-2623. (doi:10.1021/jm3012933) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58560)

M

McLeod, Robert, Kumar, Rajiv, Papadatos-Pastos, Dionysis, Mateo, Joaquin, Brown, Jessica S., Garces, Alvaro H. Ingles, Ruddle, Ruth, Decordova, Shaun, Jueliger, Simone, Ferraldeschi, Roberta, and others. (2020) First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors. Clinical Cancer Research, . ISSN 1078-0432. (doi:10.1158/1078-0432.CCR-20-0700) (KAR id:82812)
[thumbnail of McLeod et al 2020- final peer reviewed and journal approved manuscript - 237976_3_merged_1592995161.pdf]
Preview

Moreno, Lucas, Caron, Hubert, Geoerger, Birgit, Eggert, Angelika, Schleiermacher, Gudrun, Brock, Penelope, Valteau-Couanet, Dominique, Chesler, Louis, Schulte, Johannes H, De Preter, Katleen, and others. (2017) Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. Expert Opinion on Drug Discovery, 12 (8). pp. 801-811. ISSN 1746-0441. E-ISSN 1746-045X. (doi:10.1080/17460441.2017.1340269) (KAR id:63861)
[thumbnail of NDDS REVISED FINAL 16-5-17.pdf]
Preview
[thumbnail of Abbreviations]
Preview

Matthews, Thomas P., McHardy, Tatiana, Klair, Suki, Boxall, Kathy, Fisher, Martin, Cherry, Michael, Allen, Charlotte E., Addison, Glynn J., Ellard, John, Aherne, G. Wynne, and others. (2010) Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases. Bioorganic & Medicinal Chemistry Letters, 20 (14). pp. 4045-4049. ISSN 0960-894X. (doi:10.1016/j.bmcl.2010.05.096) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58572)

McHardy, Tatiana, Caldwell, John J., Cheung, Kwai-Ming, Hunter, Lisa J., Taylor, Kevin, Rowlands, Martin, Ruddle, Ruth, Henley, Alan, de Haven Brandon, Alexis, Valenti, Melanie, and others. (2010) Discovery of 4-Amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt). Journal of Medicinal Chemistry, 53 (5). pp. 2239-2249. ISSN 0022-2623. (doi:10.1021/jm901788j) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58574)

O

Osborne, James D., Matthews, Thomas P., McHardy, Tatiana, Proisy, Nicolas, Cheung, Kwai-Ming J., Lainchbury, Michael, Brown, Nathan, Walton, Michael I., Eve, Paul D., Boxall, Katherine J., and others. (2016) Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737). Journal of Medicinal Chemistry, 59 (11). pp. 5221-5237. ISSN 0022-2623. (doi:10.1021/acs.jmedchem.5b01938) (KAR id:58552)
[thumbnail of COLLINS Multi-parameter lead optimization to give an oral - Collins J Med Chem.pdf]
Preview

P

Pal, Akos, Asad, Yasmin, Ruddle, Ruth, Henley, Alan T., Swales, Karen, Decordova, Shaun, Eccles, Suzanne A ., Collins, Ian, Garrett, Michelle D., De Bono, Johann, and others. (2020) Metabolomic changes of the multi (-AGC-) kinase inhibitor AT13148 in cells, mice and patients are associated with NOS regulation. Metabolomics, 16 (4). ISSN 1573-3882. (doi:10.1007/s11306-020-01676-0) (KAR id:80866)
[thumbnail of Pal et al 2020 Metabolomics, 16, 20.pdf]
Preview

Page, Jonathan James (2017) Understanding insulin signalling and its role in regulating ageing in C elegans using pharmacological and genetic approaches. Master of Science by Research (MScRes) thesis, University of Kent,. (Access to this publication is currently restricted. You may be able to access a copy if URLs are provided) (KAR id:66732)
[thumbnail of 202MSc thesis, Jonathan Page August 2017.pdf] [thumbnail of 202MSc thesis, Jonathan Page August 2017.pdf]

R

Rogers, Rebecca F, Walton, Mike I., Cherry, Daniel L, Collins, Ian, Clarke, Paul A, Garrett, Michelle D., Workman, Paul (2020) CHK1 inhibition is synthetically lethal with loss of B-family DNA polymerase function in human lung and colorectal cancer cells. Cancer Research, . ISSN 0008-5472. (doi:10.1158/0008-5472.CAN-19-1372) (KAR id:80536)
[thumbnail of Rogers et al 2020 Cancer Research.pdf]
Preview

Reader, John C., Matthews, Thomas P., Klair, Suki, Cheung, Kwai-Ming J., Scanlon, Jane, Proisy, Nicolas, Addison, Glynn, Ellard, John, Piton, Nelly, Taylor, Suzanne, and others. (2011) Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing. Journal of Medicinal Chemistry, 54 (24). pp. 8328-8342. ISSN 0022-2623. (doi:10.1021/jm2007326) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58567)

S

Saintas, Emily, Abrahams, Liam, Ahmed, Gulshan T, Ajakaiye, Anu-Oluwa M, AlHumaidi, Abdulaziz S H A M, Ashmore-Harris, Candice, Clark, Iain, Dura, Usha K, Fixmer, Carine N, Ike-Morris, Chinedu, and others. (2017) Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-AS. PLoS ONE, 12 (2). Article Number 172140. ISSN 1932-6203. (doi:10.1371/journal.pone.0172140) (KAR id:60364)
[thumbnail of journal.pone.0172140.pdf]
Preview

Sumbayev, Vadim V., Silva, Isabel Gonçalves, Blackburn, Jennifer, Gibbs, Bernhard F, Yasinska, Inna M., Garrett, Michelle D., Tonevitsky, Alexandre G., Ushkaryov, Yuri (2016) Expression of functional neuronal receptor latrophilin 1 in human acute myeloid leukaemia cells. Oncotarget, 7 . pp. 45575-45583. E-ISSN 1949-2553. (doi:10.18632/oncotarget.10039) (KAR id:58343)
[thumbnail of Oncotarget_2016_latrophilin1.pdf]
Preview

Smith, Jennifer R., Moreno, Lucas, Heaton, Simon P., Chesler, Louis, Pearson, Andrew D.J., Garrett, Michelle D. (2016) Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma. Molecular Oncology, 10 (4). pp. 538-552. ISSN 1574-7891. (doi:10.1016/j.molonc.2015.11.005) (KAR id:55391)
[thumbnail of Smith et al-Accepted version Oct 2015.pdf]
Preview

Sadok, Amine, McCarthy, Afshan, Caldwell, John, Collins, Ian, Garrett, Michelle D., Yeo, Maggie, Hooper, Steven, Sahai, Erik, Kuemper, Sandra, Mardakheh, Faraz K., and others. (2015) Rho Kinase Inhibitors Block Melanoma Cell Migration and Inhibit Metastasis. Cancer Research, 75 (11). pp. 2272-2284. ISSN 0008-5472. (doi:10.1158/0008-5472.CAN-14-2156) (KAR id:50204)
[thumbnail of Sadok et al -Printed version.full.pdf]
Preview

T

Tappenden, Natasha Anne (2019) Investigation mechanisms of acquired resistance to CHK1 inhibitors in the human ovarian cancer cell line PEO1. Master of Science by Research (MScRes) thesis, University of Kent,. (Access to this publication is currently restricted. You may be able to access a copy if URLs are provided) (KAR id:79565)
[thumbnail of 89Investigating Mechanisms of Acquired Resistance to CHK1 Inhibitors in the Huma.pdf]

Touchefeu, Yann, Khan, Aadil A., Borst, Gerben, Zaidi, Shane H., McLaughlin, Martin, Roulstone, Victoria, Mansfield, David, Kyula, Joan, Pencavel, Tim, Karapanagiotou, Eleni M., and others. (2013) Optimising measles virus-guided radiovirotherapy with external beam radiotherapy and specific checkpoint kinase 1 inhibition. Radiotherapy and Oncology, 108 (1). pp. 24-31. ISSN 0167-8140. (doi:10.1016/j.radonc.2013.05.036) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58555)

W

Whittaker, Steven R., Barlow, Clare, Martin, Mathew P., Mancusi, Caterina, Wagner, Steve, Self, Annette, Barrie, Elaine, te Poele, Robert, Sharp, Swee, Brown, Nathan, and others. (2018) Molecular profiling and combinatorial activity of CCT068127: A potent CDK2 and CDK9 inhibitor. Molecular Oncology, 12 . pp. 287-304. ISSN 1574-7891. E-ISSN 1878-0261. (doi:10.1002/1878-0261.12148) (KAR id:64152)
[thumbnail of Whittaker et al 2017.pdf]
Preview

Walton, Mike I., Eve, Paul D., Hayes, Angela, Henley, Alan T., Valenti, Melanie R., De Haven Brandon, Alexis K., Boxall, Kathy J., Box, Gary, Tall, Matthew, Swales, Karen, and others. (2015) The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma. Oncotarget, 7 (3). pp. 2329-2342. E-ISSN 1949-2553. (doi:10.18632/oncotarget.4919) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:54924)

Wang, Qiming Jane, Silva-Santisteban, M. Cris, Westwood, Isaac M., Boxall, Kathy, Brown, Nathan, Peacock, Sam, McAndrew, Craig, Barrie, Elaine, Richards, Meirion, Mirza, Amin, and others. (2013) Fragment-Based Screening Maps Inhibitor Interactions in the ATP-Binding Site of Checkpoint Kinase 2. PLoS ONE, 8 (6). e65689. ISSN 1932-6203. (doi:10.1371/journal.pone.0065689) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58556)

Walton, Mike I., Eve, Paul D., Hayes, Angela, Valenti, Melanie R., De Haven Brandon, Alexis K., Box, Gary, Hallsworth, Albert, Smith, Elizabeth L., Boxall, Kathy J., Lainchbury, Michael, and others. (2012) CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs. Clinical Cancer Research, 18 (20). pp. 5650-5661. ISSN 1078-0432. (doi:10.1158/1078-0432.CCR-12-1322) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58558)

Walton, M. I., Eve, P. D., Hayes, A., Valenti, M., De Haven Brandon, A., Box, G., Boxall, K. J., Aherne, G. W., Eccles, S. A., Raynaud, F. I., and others. (2010) The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106. Molecular Cancer Therapeutics, 9 (1). pp. 89-100. ISSN 1535-7163. (doi:10.1158/1535-7163.MCT-09-0938) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58575)

Y

Yap, Timothy A., Yan, Li, Patnaik, Amita, Tunariu, Nina, Biondo, Andrea, Fearen, Ivy, Papadopoulos, Kyriakos P., Olmos, David, Baird, Richard, Delgado, Liliana, and others. (2014) Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers. Clinical Cancer Research, 20 (22). pp. 5672-5685. ISSN 1078-0432. E-ISSN 1557-3265. (doi:10.1158/1078-0432.CCR-14-0868) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:54928)

Yap, Timothy A., Walton, Mike I., Grimshaw, Kayla M., te Poele, Robert H., Eve, Paul D., Valenti, Melanie R., De Haven Brandon, Alexis K., Martins, Vanessa, Zetterlund, Anna, Heaton, Simon P., and others. (2012) AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity. Clinical Cancer Research, 18 (14). pp. 3912-3923. ISSN 1078-0432. (doi:10.1158/1078-0432.CCR-11-3313) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58561)

Yap, T. A., Walton, M. I., Hunter, L.-J. K., Valenti, M., de Haven Brandon, A., Eve, P. D., Ruddle, R., Heaton, S. P., Henley, A., Pickard, L., and others. (2010) Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930. Molecular Cancer Therapeutics, 10 (2). pp. 360-371. ISSN 1535-7163. (doi:10.1158/1535-7163.MCT-10-0760) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:58569)

This list was generated on Fri Jan 21 20:31:53 2022 GMT.